Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.32M | $3.96M | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Revenue growth | — | 70.8% | 156.9% | 291.5% | 11.9% | 32.0% | 26.9% |
| Operating income | -$62.4M | -$84.6M | -$183M | -$246M | -$350M | -$479M | -$648M |
| Operating margin | -2692.6% | -2135.7% | -1795.8% | -616.7% | -785.3% | -814.1% | -867.9% |
| Net income | -$61.9M | -$87.0M | -$186M | -$239M | -$328M | -$464M | -$645M |
| Net margin | -2668.3% | -2196.0% | -1832.2% | -601.0% | -736.0% | -788.0% | -863.4% |
| EPS (diluted) | -$2.87 | -$3.99 | -$1.49 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.0M | -$45.4M | -$159M | -$83.5M | -$288M | -$359M | -$372M |
| Capital expenditures | $3.91M | $5.83M | $39.8M | $37.1M | $12.0M | $13.7M | $6.47M |
| Free cash flow | -$61.0M | -$51.2M | -$198M | -$121M | -$300M | -$373M | -$378M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $75.2M | $262M | $285M | $550M | $392M | $594M | $743M |
| Total assets | — | $299M | $610M | $701M | $654M | $1.45B | $1.47B |
| Total liabilities | — | $56.6M | $67.4M | $215M | $190M | $414M | $343M |
| Long-term debt | — | — | $723K | — | — | — | — |
| Shareholders' equity | -$124M | -$206M | $543M | $486M | $463M | $1.03B | $1.13B |
| Retained earnings | — | -$214M | -$400M | -$640M | -$968M | -$1.43B | -$2.08B |
| Shares (wtd avg diluted) | 21.6M | 21.8M | 125M | 176M | 208M | 274M | 447M |
Every figure is extracted from RECURSION PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.